Analysts called a recent stock sell-off at Embecta (Nasdaq:EMBC) “unwarranted” and believe the company is moving in the right direction despite recent challenges. Late last year, Embecta filed with the state of Massachusetts to confirm a workforce reduction affecting 118 employees. This related to the company’s plans to discontinue its insulin patch pump program and restructure. […]
embecta
Embecta to lay off 118 in Massachusetts following patch pump program discontinuation
Embecta (Nasdaq:EMBC) filed with the state of Massachusetts to confirm a workforce reduction affecting 118 employees. The state received Embecta’s Worker Adjustment and Retraining Notification (WARN) submission on Nov. 26 — the same day it announced plans to discontinue its insulin patch pump program and restructure. The discontinuation of the patch pump program came not […]
Embecta discontinues insulin patch pump program, plans restructuring
Embecta (Nasdaq:EMBC) announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan. Shares of EMBC ticked up 4.3% to $14.41 apiece before hours after the company announced the discontinuation as part of its fourth-quarter earnings results. The BD Diabetes spinoff won FDA approval for a disposable patch pump system […]
The biggest diabetes tech stories of the year so far
On World Diabetes Day, it’s worth taking a look back at the last 10.5 months in the diabetes technology space. The date, which marks the birth date of the inventor of insulin, brings out all sorts of initiatives from various companies involved in innovating these technologies (read about those HERE). Those companies have contributed to […]
What diabetes tech companies are doing on World Diabetes Day 2024
World Diabetes Day — today, Nov. 14 — brings out the best in the diabetes community that continues to innovate year after year. This date serves as a time to recognize these innovations as it marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. The […]
Embecta wins FDA clearance for disposable insulin patch pump
Embecta (Nasdaq:EMBC) announced today that it received FDA 510(k) clearance for its proprietary disposable insulin delivery system. The open-loop system is indicated for adults who require insulin to manage diabetes, including both type 1 and type 2 diabetes. It features a tubeless design with a 300-unit insulin reservoir, informed by feedback from people with type […]
The 9 largest diabetes technology companies in the world
Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in all shapes and sizes, too. Some focus entirely (or almost entirely) on solutions for people with diabetes. Others are much larger medtech firms that still have sizable business units that focus […]
Embecta stock gets a boost on Q3 beats, patch pump program remains on track
Embecta (Nasdaq:EMBC) shares rose significantly today on third-quarter results that came in well ahead of the consensus forecast. Shares of EMBC ticked up 14% to $16.39 apiece in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose slightly. It’s the second recent boost for Embecta’s […]
GenPact partners with Embecta to support diabetes market efforts
Genpact announced today that it teamed up with Embecta (Nasdaq:EMBC) to support the company in the diabetes technology market. The company says it has been working with Embecta to support its spinoff from BD and subsequent evolution as a company. “From the beginning, our relationship was rooted in shared values and a commitment to mutual […]
Embecta stock rises on reports that it might look to sell
Financial Times reports that Embecta (Nasdaq:EMBC), the former diabetes unit at BD, hired advisers to look into a possible sale of the company. Shares of EMBC ticked up 16.5% to $15.34 apiece in early-morning trading today. The company has operated as a standalone, publicly-traded company since April 2022, when it completed its spin-off from BD. […]
